ESPE Abstracts (2018) 89 P-P2-334

aASP Cosenza, cetraro, Italy; bMagna Graecia University, Catanzaro, Italy


We report a case of a 10-year-old girl born at 41st week and spontaneous birth, in therapy with analogous GnRH for idiopathic central puberty. At 4 years bilateral thelarche, performed first and second level investigations and recives diagnosis of early idiopathic central puberty. Since then, therapy with triptorelin 3.75 mg i.m every 21 days was administrated. Regular checks, good compliance, and response to therapy. At 10 years old recurring episodes of headache and vertigo. Clinical examination was negative. Height 1.5 SDS, weight −0.3 SDS, Tanner stage was P2 B1. Blood pressure (BP) was 124/90 mmHg (95–99th centile for systolic and >99th centile for diastolic). Pressure values were confirmed in several ambulatory and home assessment and were suggestive of stage I hypertension. Ambulatory BP monitoring revealed: mean 24 h systolic/diastolic BP 116/79 mmHg, mean day time and night time systolic/diastolic BP 118/80 and 110/73 respectively, nocturnal dipping 8.7%, and diastolic BP load 39.9%, confirming a stage I hypertension. Electrocardiography and echocardiography were normal. Renovascular and renal parenchymal diseases and endocrine causes of hypertension were excluded. Considering the girl symptomatology, anti-hypertensive therapy was started (Enalapril 0.15 mg/kg/die). No improvement of BP values were observed and GnRH-analog therapy was discontinued. Later the girl showed normalisation of BP values, and Enalapril was stopped. To date BP values persists on normal range for sex, age and height. Triptorelin is a GnRH agonist used for treatment of central precocious puberty because it suppresses pituitary gonadotropin secretion when administered continuously. Tolerance to GnRH agonist is usually good, although adverse effects such as headaches, rash, gastrointestinal compliants were observed. In the last years few case reports were published, suggesting a link between GnRH agonist treatment and hypertension. If we consider that: I) the patient had a normotensive condition at the beginning of therapy, II) blood pressure returned to normal values after discontinuation of triptorelin and, III) normal BP values were maintained even after antihypertensive drugs withdrawal, we suggest that hypoestrogenism induced by GnRH agonist treatment might have played a role in the development of high BP.

Volume 89

57th Annual ESPE (ESPE 2018)

Athens, Greece
27 Sep 2018 - 29 Sep 2018

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.